EMPAGLIFLOZIN

Brand name:

• Jardiance®

Pharmaceutical company:

Boehringer Ingelheim Pty Ltd

Condition/indication:
(therapeutic use)

• Chronic heart failure

PBAC Submission type:

Change to listing (–)

Comment:

--

Public Summary Document:

Public Summary Documents – November 2021

Related medicines:

--

Submission received for:

November 2021 PBAC meeting

Opportunity for consumer comment:

Open 28/07/2021 and close 22/09/2021 (see PBS Website)

PBAC meeting:

Held on 03/11/2021

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

14/12/2021

Lodgement of required documentation:

22/12/2021

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 20/01/2022

Status:

Finalised

Government processes:

Commenced on 24/01/2022

Medicine listed on the PBS:

01/04/2022 (see PBS schedule)

---